Overview

Suviray 70 mg Injection contains an active component of Erenumab. It belongs to the class of medicines called monoclonal antibodies. This medication is used for the preventive treatment of migraines in abdults.  Migraine is a neurological disorder characterized by recurring and intense headaches, often accompanied by other symptoms such as nausea, sensitivity to light, and visual disturbances. For individuals who have not responded well to or have contraindications to other migraine preventive medications, Suviray 70 mg Injection provides an alternative treatment option. It is not recommended to use this medicine if you are allergic to the active compound Suviray 70 mg Injection and its compounds. If you have a history of hypersensitivity reactions to biologic agents or other injectable treatments, you should discuss this with your healthcare provider before starting Suviray 70 mg Injection. It is not recommended to use in children and adolescents under 18 years old. The use in elderly individuals needs close monitoring.